161 related articles for article (PubMed ID: 37160242)
1. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy.
Frazier JD; Stoudenmire LL; Wagner JL; Thomas GM; Steele GM; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2023 Jul; 62(1):106842. PubMed ID: 37160242
[TBL] [Abstract][Full Text] [Related]
2. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
4. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
5. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study.
Pascale R; Maccaro A; Mikus E; Baldassarre M; Tazza B; Esposito F; Rinaldi M; Tenti E; Ambretti S; Albertini A; Viale P; Giannella M; Bartoletti M
J Glob Antimicrob Resist; 2022 Sep; 30():390-394. PubMed ID: 35878780
[TBL] [Abstract][Full Text] [Related]
6. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
7. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
Monteagudo-Martínez N; Solís-García Del Pozo J; Nava E; Ikuta I; Galindo M; Jordán J
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1477-1489. PubMed ID: 32981375
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin in Gram-positive periprosthetic joint infections.
Simon S; Frank BJH; Hartmann S; Hinterhuber L; Reitsamer M; Aichmair A; Dominkus M; Söderquist B; Hofstaetter JG
J Antimicrob Chemother; 2022 Jul; 77(8):2274-2277. PubMed ID: 35678452
[TBL] [Abstract][Full Text] [Related]
9. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy.
Rehm S; Campion M; Katz DE; Russo R; Boucher HW
J Antimicrob Chemother; 2009 May; 63(5):1034-42. PubMed ID: 19264792
[TBL] [Abstract][Full Text] [Related]
10. An Automated, Pharmacist-Driven Initiative Improves Quality of Care for Staphylococcus aureus Bacteremia.
Wenzler E; Wang F; Goff DA; Prier B; Mellett J; Mangino JE; Bauer KA
Clin Infect Dis; 2017 Jul; 65(2):194-200. PubMed ID: 28379326
[TBL] [Abstract][Full Text] [Related]
11. Relative efficacy of cefuroxime versus dicloxacillin as definitive antimicrobial therapy in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-score adjusted retrospective cohort study.
Rasmussen JB; Knudsen JD; Arpi M; Schønheyder HC; Benfield T; Ostergaard C
J Antimicrob Chemother; 2014 Feb; 69(2):506-14. PubMed ID: 24078468
[TBL] [Abstract][Full Text] [Related]
12. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care.
Johnson TM; Molina KC; Miller MA; Kiser TH; Huang M; Mueller SW
Int J Antimicrob Agents; 2021 Apr; 57(4):106310. PubMed ID: 33609718
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.
Gudiol C; Cuervo G; Shaw E; Pujol M; Carratalà J
Expert Opin Pharmacother; 2017 Dec; 18(18):1947-1963. PubMed ID: 29115883
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
15. Impact of a pharmacist-driven care package on Staphylococcus aureus bacteremia management in a large community healthcare network: A propensity score-matched, quasi-experimental study.
Smith JR; Frens JJ; Snider CB; Claeys KC
Diagn Microbiol Infect Dis; 2018 Jan; 90(1):50-54. PubMed ID: 29153470
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
[TBL] [Abstract][Full Text] [Related]
17. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2020.
Coombs GW; Daley DA; Yee NWT; Shoby P; Mowlaboccus S
Commun Dis Intell (2018); 2022 Apr; 46():. PubMed ID: 35469556
[TBL] [Abstract][Full Text] [Related]
18. Association between treatment duration and mortality or relapse in adult patients with Staphylococcus aureus bacteraemia: a retrospective cohort study.
Abbas M; Rossel A; de Kraker MEA; von Dach E; Marti C; Emonet S; Harbarth S; Kaiser L; Uçkay I
Clin Microbiol Infect; 2020 May; 26(5):626-631. PubMed ID: 31357013
[TBL] [Abstract][Full Text] [Related]
19. Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
Zinzi D; Vlachaki I; Falla E; Mantopoulos T; Nathwani D
Eur J Health Econ; 2022 Nov; 23(8):1371-1381. PubMed ID: 35113269
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
Hakim A; Braun H; Thornton D; Strymish J
Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
